normalize their IgG levels showed a higher frequency of severe infections and autoimmune disease (p<O.Ol). Moreover, they expressed a reduced frequency of IgM and switched memory B cells (p<O.Ol) and an inability to produce IgG in vitro (p<O.02). We conclude that most patients with an initial diagnosis ofTHI spontaneously recover within 24 months of age and have a benign clinical course, while a subgroup of children with undefined hypogammaglobulinemia share a clinical and immunological profile with other primary immunodeficiencies. Early recognition of children with hypogammaglobulinemia during infancy who are likely to suffer from permanent immunodeficiencies later in life would allow prompt and appropriate laboratory and clinical interventions.
Over the past decade, molecular medicine and genetics have made large contributions in the diagnosis of many primary immunodeficiencies and in the understanding of innate and adaptive immunity. However, diagnosis of transient hypogammaglobulinemia of infancy (THI) is nowadays initially suspected on the exclusion of other hypogammaglobulinemia conditions and later confirmed with normalization of serum IgG levels. THI is commonly considered a transient immunodeficiency disorder due to an extension of the physiologic hypogammaglobulinemia of infancy with delay in maturation of antibody production until 36 months of age (1) (2) (3) . Currently, in the young child with recurrent infections, low isolated IgG levels and B cells >2%, there are no clinical features or diagnostic tests that differentiate self-limiting THI from permanent immune defects. The prevalence of this condition is also difficult to ascertain. It has been described as relatively uncommon, although in Japan the disorder represents 18.5% of all primary immunodeficiency disorders (4) . According to Walker et al., THI appears to have a prevalence similar to symptomatic selective IgA deficiency (SIgAD) (5) . The controversy concerning the frequency of THI may be explained by the fact that it is not necessarily associated with serious clinical symptoms and such cases remain undetected. There is no known genetic basis for this disorder, although an increased incidence has been documented in family members of patients with other immunodeficiencies (3) (4) (5) (6) . A delayed maturation of B cell function (7) , a defect in T cell maturation (8) , and upregulation of IL-12 (9) have been advocated as putative pathogenic mechanisms. Age also plays a significant role in the interpretation of this disorder. It is generally accepted that neonatal adaptive immunity is immature, but quantitative and qualitative differences between newborn and adult cells need to be further dissected. Hence, THI disorder may represent a human model to follow the development of the B-cell response in early life with profound implications for pediatric immunotherapy and vaccination. In the present study we assess the clinical and immunological features of children with an initial THI diagnosis enrolled within the Italian Primary Immunodeficiency Network, in relation to normalization of their IgG levels and clinical outcome. We also focused on the evaluation of memory B cell subsets and in vitro immunoglobulin production to further assess the role of these parameters as predictors of the clinical evolution of this disorder into permanent immune defects.
MATERIALS AND METHODS

Patients
In 2003, a Diagnostic and Therapeutical Protocol for THI was formulated and adopted in the context of the Immunodeficiency Strategic Committee of the Italian Association of Pediatric Haematology and Oncology (AIEOP) and the Italian Primary Immunodeficiency Network (IPINET) (https://www.aieop.org/stdoc/ prot/rec_thi_en_06.pdf). Thirteen Specialized Centres provided information regarding patients' personal, clinical and immunological data as well as family pedigree. Seventy-seven patients with an initial diagnosis of THI were enrolled according to the following criteria: a) age ranging from 12 to 36 months, b) IgO serum levels < 2SD of age matched reference values (10) , some also associated with low IgA and/or IgM, c) circulating B cells > 2%; d) exclusion of other hypogammaglobulinemia conditions, i.e. drugs, genetic disorders, chromosomal abnormalities, infectious diseases, neoplasia and systemic disorders. During this three-year period, an annual follow-up questionnaire was prospectively updated with the clinical and immunological status of the 57 patients and, according to normalization of IgO values or not, initial THI diagnosis was confirmed or persistent hypogammaglobulinemia was ascertained. Informed consent was obtained from the patients' parents. The study was approved by the Institutional Review Board (lRB).
Laboratory studies
At initial diagnosis, immunological evaluation included serum Ig quantification by nephelometry, IgG subclass measurement by radial immunodiffusion and enumeration of T and B lymphocyte subsets by FACS analysis using anti-CD3, -CD4, -CD8, -CDI9 or -CD20 monoclonal antibodies. Specific anti-tetanus, anti-hepatitis Band anti-pneumococcal capsular polysaccharides (antiPn PS) antibody levels were obtained by ELISA (Binding Sites, Birmingham, England). Furthermore, IgG and IgA specific antibodies to pneumococcal serotypes 1, 4 and 14 (PnPS; American Type Culture Collection, Manassas, VA) were tested before and 4-6 weeks after administration of two doses of 0.5 ml conjugate vaccine (Prevenar, Wyeth, Europe) and/or polysaccharide vaccine (Pneumo 23, Aventis Pasteur MSD) as previously described (l1). After these preliminary laboratory evaluations, B cell memory subsets and Ig in vitro production were evaluated according to outcome.
B cell memory subsets
Mononuclear cells were stained with the appropriate antibody combinations of fluorescein, phycoerythrin, APC, cychrome, or biotin-labeled antibodies followed by streptavidin-cychrome and streptavidin-APC (Caltag, San Francisco, Calif). Monoclonal antibodies anti-CDS (clone UCHT2), anti-CDl9 (clone HIB 19), anti-CD22 (clone HIB22), anti-CD27 (clone M-T271), anti-lgM (clone G20-127), and anti-lgD (clone IA6-2) were obtained from Pharmingen (San Diego, Calif) and anti-lgM Fc51l fragment specific antibody was obtained from Jackson ImmunoResearch Laboratories (West Grove, PA). All analyses were performed on a FACSCalibur® (Becton and Dickinson, Sunnyvale, Calif) interfaced with a Macintosh CeltQuest" computer program. One hundred thousand events per sample were analyzed.
In vitro Immunoglobulin Production
Spontaneous and polyclonally stimulated in vitro Ig production was evaluated in peripheral blood mononuclear cells (PBMCs) by a previously described method (l2). Briefly, PBMCs (l05/well) were cultured, alone or in the presence of Zxl Ovwell irradiated (70 Gy) CDw32 L cells (LGC Promochem, Teddington, UK), 0.5 ug/ml anti-CD40 mAb (Calbiochem, Merck KGaA, Darmstadt, Germany), and 200 ng/ml recombinant human interleukin-l0 (rhIL-I0, R&D Systems hie, Minneapolis, MN). All cultures were performed in Iscove's medium, supplemented with 5 ug/ml bovine insulin, 0.5% bovine serum albumin, 2 ug/ml ethanolamine, 20 mM Hepes buffer (all from Sigma-Aldrich Corporation, St Louis, MO), 50 ug/ml gentamycin, 2 mM L-glutamine and 5% heat inactivated foetal bovine serum (all from Gibco, Life Technologies Ltd, Paisley, UK). All experiments were run in triplicate at a final volume of 200 ul/well. The supernatants were harvested after 13 days incubation at 37°C in humidified 5% CO 2 ,
Ig quantification in supernatant
IgG, IgA and IgM concentrations in the supernatant were determined by an ELISA technique, as previously described (l2). Briefly, microtiter plates (Greiner Bio-One, Frickenhausen, Germany) were coated with rabbit anti-hlgG or anti-hlgA or anti-hlgM antibody (Dako Cytomation, Glostrup, Denmark) incubated for 3 hours at 37°C and overnight at 4°C. The diluted supernatants were incubated for 2 hours at 37°C; then, rabbit anti-hlgG or anti-hlgA or anti-hlgM antibodies conjugated to horseradish peroxidase (Dako Immunoglobulins) were added. The concentration of each isotype was extrapolated from the standard curve included in each plate and expressed as ug/ml/I 0 6 B cells.
Statistical analysis
All information was stored, controlled and analyzed by VENUS, an integrated software system run on an IBM mainframe at the North-Eastern Italian Interuniversity Computing Center (CINECA). The Fisher's exact test was used to compare differences in percentages for categorical variables, whereas the student's t test was adopted to compare the mean for continuous variables. Chi square for trend was used to analyze tendency ofTHI patients for serum IgG normalization. All p values are two-sided and values less than 0.05 were considered significant.
RESULTS
Clinical and immunological characteristics of 77 patients at initial diagnosis ofTHI
Fifty-five males (71%) and 22 (29%) females were enrolled in the study. Positive family history for immunodeficiencies was reported in four patients, in one of them consanguinity was also present. Seventy patients showed clinical symptoms with a mean age at presentation of 10 months (range 1 -35 mo). Clinical manifestations were grouped by infection, allergy and autoimmunity as detailed in Table I . Respiratory tract infections were the most prevalent events (83%), 33 patients (47%) suffered from allergies and three (4%) from autoimmune disease, two of whom had autoimmune neutropenia (4) (23%) and the ability to produce specific antibodies to tetanus and hepatitis B protein antigens was reduced in 7/44 (16%) and 8/46 (17%) patients, respectively. Twenty-seven patients were immunized with at least two doses of the conjugated pneumococcal vaccine (Prevenar) and/or unconjugated vaccine (Pneumo 23); 26 had an adequate response 4-6 weeks following immunizations, as defined by a > 4-fold increase in pre-vaccination titer. The only poor responder was a 31 month-old boy whose older brother suffers from common variable disease. Percentages of CD3, CD4, CD8, mature B cells (CD22+CD27-) (69.5% ± 6.9%), transitional B cells (CD24brighl CD38brighl) (10.6% ± 6.8%) and memory B cells (CD24+CD27+) (13% ± 5.3%) were comparable to those found in healthy age-matched controls.
Clinical and immunological characteristics of 57 putative THI patients at follow-up
Fifty-seven putative THI patients (mean age 30 months) were followed during a three year period (mean follow-up 13 months). Forty-one children (72%) spontaneously reached normal IgG values and were confirmed as children with THI; 16 children (28%) had persistently low IgG levels and were identified as hypogammaglobulinemic children (Hypogamma). Two Hypogamma patients had a positive family history for immunodeficiencies and consanguinity was also present in one of them. Thirty THI patients normalized all three isotypes, whereas two patients remained IgA deficient, seven IgM deficient and two both IgA and IgM deficient. Hypogamma patients exhibited no change in their pre-existing deficiencies. As shown in Fig. 1 , normalization of IgG values occurred in 29/41 (71%) THI patients within 24 months of age, in four within 24-36 months and in eight up to the age of 60 months (p<O.OO1). At initial diagnosis, IgG and IgA levels did not significantly differ in the THI and Hypogamma patients ( Fig. 2a,  2b) . At follow-up, in both groups, serum IgG ( Fig.  2a) and IgA (Fig. 2b ) levels significantly increased (p<O.Ol). However, at follow-up THI children showed significantly higher IgG concentrations than Hypogamma children (546 ± 159, 343 ± 89.87 mg/dl, respectively; p<O.Ol). The persistence of low IgG levels in children >24 months of age could be predictive of immunodeficiencies other than THI, since the majority of our THI patients had corrected their levels by this time. As shown in Fig. 2c , IgM serum concentrations did not show any significant variation over time and within groups. In keeping with the positive outcome in the majority of patients, infections became less severe and less prevalent, with recurrent upper respiratory infections representing the most relevant clinical complaint in THI children (Table III) . In contrast, a significantly higher number of patients with more severe disease, i.e. pneumonia, gastrointestinal and urinary tract infections and autoimmune disease, was found in the Hypogamma group (p<0.01). Up to the last followup visit, resolution of clinical symptoms occurred in 16 (39%) THI and 7 (44%) Hypogamma patients.
B cell evaluation in children with definitive diagnosis ofTHI and Hypogamma
In a preliminary study we demonstrated that a subgroup ofchildren with an initial putative diagnosis of THI share common B cell abnormalities with CVID patients (13) . In a limited number of patients, we found IgM memory B cells and switched memory B cells to be significantly reduced in children with persistent hypogammaglobulinemia (13) . To further assess the contribution of B cell memory subsets to the hypogammaglobulinemia state over time we investigated samples from 20 patients at initial diagnosis (14 THI-median age: 19 months; and 6 Hypogamma-median age: 26 months) and from 19 patients at follow up (10 THI-median age 33,6 months; and 9 Hypogamma-median age 43 months) compared to age-matched controls. As shown in Fig. 3 , consistent with our previous observations (13), even after adjusting for age-matched controls, IgM and switched memory, B cells increased with age with no significant differences between the THI versus control or Hypogamma groups. However, at follow up, Hypogamma patients shewed a. significant reduction in IgM and switched memory , ,-
., ) o:;" yj,:: (Fig. 3b,  d) . The lower percentages of the switched memory B cells in Hypogamma patients (4.25% versus 7.4% in controls, p<0.05) was already present at diagnosis (Fig.3c) . The functional capacity of B cells to produce Ig in vitro over time was tested in 13 THI children with an initial diagnosis of THI (8 THI and 5 Hypogamma) and in 24 children at follow-up (17 THI and 7 Hypogamma). As observed in agematched controls, non-stimulated PBMCs from THI patients secreted low immunoglobulin levels (data not shown), without differences between patient groups. Stimulated PBMC from THI and Hypogamma showed an increase in IgG, IgA and IgM secretion and in vitro IgG values in THI both at diagnosis and follow-up (median: 65, range 7-331 ug/ml/Iu" CD19+; median: 196, range 23-616 ug/ml/I 0 6 CD 19+, respectively) were not different from those found in Hypogamma (median: 156, range 51-426 ug/ml/I 0 6 CD 19+; median: 79, range 41-462 ug/ml/Iu" CD19+, respectively) ( Fig. 4 ). However, an increased in vitro IgG production in the follow-up sample of THI patients was observed. This is in agreement with the benign course of the disorder in these patients. In contrast, in vitro IgG production remained very low in the Hypogamma group. The low in vitro IgG production observed in Hypogamma children was maintained over 24 months of age. No correlation was found between serum immunoglobulin levels and in vitro antibody < 24 24 -36 > 36
Age (mo n t hs) Fig. 1 . Age-group distribution (%) in 41 THI patients at follow up. *p < 0.001. production (data not shown).
DISCUSSION
By definition, the diagnosis of THI can only be established in retrospect when a child's immunoglobulin values reach age-appropriate levels. Some of the children with hypogammaglobulinemia of unknown cause do not recover from this defect and may develop selective IgA deficiency, CVID or other dysgammaglobulinemias (14) (15) .
In this first extensive study of children with an initial diagnosis of THI, we provide a prospective view of the disorder, with a number of relevant clinical and immunological observations. Consistent with other reports (16) (17) (18) (19) , most of our patients were initially evaluated for a history of recurrent infections, and decreased IgG values were found during a routine immunological workup. Indeed, the majority of them had experienced at least one episode of infection alone or associated to allergy or autoimmunity. Moreover, at follow-up, some patients showed severe infections, requiring in some cases PAT and IVIG therapy, autoimmune disease resembling selective IgA deficiency and/or CVID. In our patients, at diagnosis, low serum IgG were often associated with low specific antibody response to protein and polysaccharide vaccines. In contrast with previous reports (8, (20) (21) (22) , this observation reduces the importance of specific antibody testing to distinguish putative THI from more complex immunodeficiencies such as XLA and CVID. In our experience, normalization of IgG within 24 months of age, occurred in more than 70% of THI patients. In the Hypogamma group, a higher frequency of IgA and/or IgM deficiency was observed. This observation, in keeping with other studies (14) (15) , suggests that some patients with initial diagnosis of THI may develop a sIgAD or CVID. Moreover, our data support the hypothesis that THI, CVID and sIgAD are disorders that share common clinical manifestations, and the eventual progression of THI towards sIgAD and of sIgAD towards CVID further suggests a common genetic basis.
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